Search
Flucloxacillin
go.drugbank.com/drugs/DB00301ApprovedInvestigationalWithdrawnAntibiotic analog of cloxacillin.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersVoxelotor
go.drugbank.com/drugs/DB14975ApprovedVoxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesPemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigationalPemigatinib is a small molecule kinase inhibitor with antitumour activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells. FGFRs ga...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsTelisotuzumab vedotin
go.drugbank.com/drugs/DB15104ApprovedInvestigationalTelisotuzumab vedotin is an antibody-drug conjugate comprising telisotuzumab, a c-Met-directed humanized IgG1κ monoclonal antibody, conjugated to monomethyl auristatin E (MMAE), a small molecule microtubule-disrupting agent, via a protea...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsFluciclovine
go.drugbank.com/drugs/DB15237InvestigationalFluciclovine is under investigation in clinical trial NCT03036943 (Fluciclovine (18F) Imaging of Breast Cancer).
Categories: P-glycoprotein inhibitorsTovorafenib
go.drugbank.com/drugs/DB15266ApprovedInvestigationalTovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity. It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, wi...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersBelantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawnBelantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF). Belantamab mafodotin was granted FDA accelerated a...
Categories: P-glycoprotein substratesChamazulene
go.drugbank.com/drugs/DB15931ExperimentalCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2D6 InhibitorsCinnamon oil
go.drugbank.com/drugs/DB15986ApprovedInvestigationalCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsJBPOS0101
go.drugbank.com/drugs/DB16034InvestigationalJBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients).
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers